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Abstract. The aim of the present study was to investigate 
the osteogenic capability of rat calvarial periosteal cells in 
hypoxic conditions in vitro. Periosteum was obtained from 
the calvarial bone of Sprague-Dawley rats. Following primary 
tissue culture, subcultured cells were used in hypoxic or normal 
conditions. On days 1, 2, 3 and 4 following the cell culture, cell 
proliferation and mRNA and protein expression levels were 
evaluated. No significant difference in the cell proliferation rate 
was found between the normal and hypoxic condition groups. 
The hypoxic condition group exhibited a stronger expression of 
hypoxia-inducible factor (HIF)1α, vascular endothelial growth 
factor (VEGF), Runx2, alkaline phosphatase (ALP), bone 
sialoprotein (BSP), osteocalcin (OCN) and periostin at the 
mRNA level compared to that of the normal condition group. 
The hypoxic condition group also exhibited a stronger expres-
sion of HIF1α, VEGF, bone morphogenetic protein (BMP)2, 
Runx2, ALP and BSP at the protein level compared to that 
of the normal condition group. In conclusion, periosteal cells 
cultured in hypoxic conditions demonstrated activated osteo-
genic capability in vitro. 
Introduction
Bone regeneration therapy is becoming common in regen-
erative medicine, and is used in the treatment of bone defects 
caused by periodontal disease and mandibular tumor resection. 
Bone marrow is often used as the typical vital material for bone 
regeneration; however, this requires an intricate procedure for 
harvesting. Recently, the periosteum has been cited as a bone 
supplement material that could be used as an alternative to bone 
marrow (1). There have also been reports that the periosteum 
has an osteogenic capability that is as high as bone marrow, 
which is often used for transplants in the maxillofacial area (2). 
A number of studies have been performed on the osteogenic 
capability of periosteal transplants (3,4). At present, collected 
periosteum is starting to be cultivated and clinically applied as 
a bone supplement (5-8).
However, it is not so easy to obtain the quantity of perios-
teum required for bone regeneration. To proliferate a sufficient 
quantity of cells for transplant, cell culture is known to be a 
good method. Furthermore, it is known that osteogenic capa-
bility is accelerated by changes in the environment, such as 
oxygen conditions. Miescher et al (10) as well as others (9,11) 
have reported that a hypoxic condition increased red blood 
cells and had various other effects on cells, such as the activa-
tion of glycolytic pathways and the induction of angiogenesis. 
Amemiya K et al (12) and Amemiya H et al (13) reported on 
the accelerated osteogenic capability of pulp cells and peri-
odontal ligament cells in hypoxic conditions. However, no 
comparisons have been made to date regarding the osteogenic 
capability of periosteal cells in hypoxic and normal conditions. 
The purpose of this molecular biological study was to investi-
gate the osteogenic capability of the cultured periosteal cells 
of rats when incubated under hypoxic conditions.
Materials and methods
This study was conducted in compliance with the Guidelines 
for the Treatment of Experimental Animals at the Tokyo 
Dental College (approval number 226102).
Animals and cell culture. Periosteal explants were harvested 
from the calvaria of 20 male Sprague-Dawley 7-week-old rats, 
each weighing approximately 250 g (Sankyo Labo Service, 
Tokyo, Japan). The skin incision was made and underlying 
muscular fibrous connective tissue was removed to expose the 
periosteum. The periosteum was stripped off mechanically 
using fine forceps. The obtained periosteum was mechani-
cally cut into sections approximately 2x2 mm in size. The cut 
periosteum was placed with the osteogenic (cambium) side 
down onto the surface of 35-mm culture dishes for 30 min, 
then culture medium was added and the dishes were cultured 
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for 4 days. For the culture, Medium 199 containing 10% 
fetal bovine serum and 50 µg/ml gentamicin, supplemented 
with 10-8 M dexametasone, 10 mM β-glycerophosphate and 
50 µg/ml ascorbic acid was used (13).
To set the oxygen conditions, a BL-40 M CO2 incubator 
(JuujiField Labo; Bio Labo, Tokyo, Japan) which regulates the 
condition of oxygen in the air to nitro-oxygen was used. For 
the hypoxic condition group, cells were incubated in a humidi-
fied atmosphere at conditions of 5% O2, 5% CO2 and 90% N2 
at 37˚C. For the normal condition group, cells were incubated 
in a humidified atmosphere at normal conditions of 20% O2, 
5% CO2 and 75% N2 at 37˚C (15).
Cell proliferation assay. Subcultured cells from each group 
were harvested with 0.25% trypsin and 0.02% EDTA, and 
approximately 3x103 cells were seeded onto the 35-mm culture 
dishes. At 1, 2, 3 and 4 days after the culture, the cells were 
washed with phosphate-buffered saline (PBS) and harvested 
using 0.25% trypsin and 0.02% EDTA. The number of cells was 
counted using a Vi-CELL™ Coulter counter (Beckman Coulter, 
Inc., Fullerton, CA, USA).
Quantitative reverse transcription-polymerase chain reac-
tion (RT-PCR). Approximately 3x104 cells from each group 
were seeded in 35-mm dishes and cultured as detailed 
above. Total RNA was extracted from each sample using 
the acid guanidium thiocyanate/phenol-chloroform method 
as follows. The culture medium was removed and cells 
were rinsed twice using PBS. The cells were homogenized 
in 1 ml TRIzol reagent (Invitrogen, Grand Island, NY, 
USA) after 1, 2, 3 and 4 days of incubation. Each solution 
was transferred to a 1.5 ml tube containing chloroform and 
mixed. The tubes were centrifuged at 13,200 rpm at 4˚C for 
20 min, after which the supernatants were placed in 1.5 ml 
tubes containing 250 µl 100% isopropanol (half the amount 
of the TRIzol reagent) at -80˚C for 1 h. Following centrifuga-
tion at 13,200 rpm at 4˚C for 20 min, the supernatants were 
discarded and the remaining total RNA pellets were washed 
with 70% cold ethanol. Total RNAs were dissolved in 50 µl 
RNase-free (diethylpyrocarbonate-treated) water and then 
reverse transcribed and amplified in 20 µl volumes using a 
reverse transcription kit (QuantiTect; Qiagen, Germantown, 
MD, USA) containing RNA polymerase chain reaction (PCR) 
buffer (2 U/µl RNase inhibitor, 0.25 U/µl reverse transcrip-
tase, 0.125 µM oligo(dT) adaptor primer and 5 mM MgCl2 
in RNase-free water) (13). RT-PCR products were analyzed 
by quantitative real-time RT-PCR using a TaqMan gene 
expression assay (Applied Biosystems, Inc., Foster City, CA, 
USA) for the target genes: Hypoxia-inducible factor (HIF)1α 
(Rn00577560_m1, 72 bp), vascular endothelial growth factor 
(VEGF) (Rn00582935_m1, 75 bp), alkaline phosphatase 
(ALP) (Rn01516028_m1, 68 bp), bone sialoprotein (BSP) 
(Rn01450118_m1, 89 bp), osteocalcin (OCN) (Rn01455285_g1, 
81 bp), Runx2 (Rn01512296_m1, 116 bp). The TaqMan 
endogenous control (Applied Biosystems) for the target gene 
β-actin (Rn01768120_m1, 63 bp) was used as an endogenous 
control. All PCR reactions were performed using a real-time 
PCR 7500 fast system (Applied Biosystems). Gene expression 
quantification using TaqMan gene expression assays was 
performed as the second step in a two-step RT-PCR. Assays 
were performed in 20 µl single-plex reactions containing 
TaqMan Fast Universal PCR Master mix, TaqMan gene 
expression assays, distilled water and complementary DNA 
according to the manufacturer's instructions. Reaction condi-
tions consisted of 50 cycles at 95˚C for 3 sec and at 62˚C 
for 30 sec.
ALP activity. ALP activity was measured using a colormetric 
assay kit (Alkaline Phosphatase Opt; Roche Diagnostics 
Japan, Tokyo, Japan). Cultured cells (3500 cells per well) were 
washed with calcium- and magnesium-free PBS at each time-
point, and harvested with demineralized and distilled water for 
60 sec using a sonicator (Sonifier 250D; Branson, Rochester, 
MI, USA) on ice. Each homogenate was centrifuged at 800 x g 
for 5 min and the supernatants were used for assay. One milli-
liter of premixed solution (1 M diethanolamine buffer, pH 9.8, 
with 0.5 mM MgCl2 and 10 mM p-nitrophenylphosphate, kept 
at 37˚C) was added to 10 µl supernatant. Absorption at 405 nm 
for p-nitrophenol was measured using a spectrophotometer 
(Ultrospec 3000; Amersham Pharmacia Biotechnologies, 
Rochester, NY, USA). To determine the specific activity of 
ALP, protein concentrations in each lysate were determined 
using the Pierce bicinchoninic acid protein assay (Pierce, 
Rockford, IL, USA). A volume of 100 µl of each cell lysate was 
added to 100 µl bicinchoninic acid working reagent (kept at 
37˚C for 30 min). Absorbance was measured at 595 nm using 
a microplate reader. ALP activity was calculated according to 
the manufacturer's instructions.
Western blot analysis. The expression of HIF1α, bone morpho-
genetic protein (BMP)2, Runx2, BSP, OCN, VEGF, Glut1 
and periostin in periosteal cells was assessed by western blot 
analysis. Blocking was performed by PVDF blocking reagent 
to confirm specific and non-specific bands. Periosteal cells 
were seeded in 60-mm cell culture dishes and were cultured 
for 4 days. After each culture period, the cells were washed 
with CMF-PBS, and resuspended in radio-immunoprecipita-
tion assay buffer for 60 sec using a sonicator (Branson) on 
ice. Each homogenate was further stirred using a tube rotator 
(As One) for 20 min and then centrifuged at 9,300 x g for 
20 min at 4˚C. The protein concentration of each superna-
tant was measured using the Nowak method (16). Samples 
(30 µg protein each) were electrophoresed in 7.5% sodium 
dodecyl sulfate polyacrylamide gels and were transferred 
to nitrocellulose membranes using standard methods (12). 
Primary antibodies were used at a dilution of 1:1000. These 
antibodies comprised rabbit polyclonal antibodies against 
Figure 1. Cell proliferation rate. No difference was noted between the 
hypoxic and normal condition groups at any of the time-periods.
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HIF1α, BMP2, Runx2, BSP, OCN, VEGF, Glut1 and periostin. 
As a secondary antibody, horseradish peroxidase (HRP) conju-
gated anti-rabbit IgG antibody was used. Specifically bound 
antibodies were detected on the film with an enhanced chemi-
luminescence detection system (ECL Western blot detecting 
system; Amersham Pharmacia Biotech, Piscataway, NJ, USA). 
Images were analyzed using NIH Image (Scion Corporation, 
Frederick, MD, USA) and each density was normalized with 
actin from the same sample.
Statistical analysis. The results were analyzed using one-way 
analysis of variance (ANOVA) and then compared by Scheffe's 
test.
Results
Cell proliferation rate. There was no significant difference 
in the cell proliferation rate between the normal and hypoxic 
condition groups (Fig. 1).
mRNA expression (RT-PCR). HIF1α expression was higher 
in the hypoxic condition group than in the normal condition 
group on days 1, 2, 3 and 4 (P<0.05). VEGF expression was 
significantly higher in the hypoxic condition group than 
in the normal condition group on days 3 and 4 (P<0.05). In 
particular, a significantly high value was indicated on day 3 
(P<0.01). Runx2 expression was significantly higher in the 
Figure 2. mRNA expression. (A) HIF1α mRNA expression in the hypoxic condition group was significantly higher than that in the normal condition group at 
all of the time-periods. (B) VEGF mRNA expression in the hypoxic condition group was significantly higher than that in the normal condition group on days 2 
and 3, but was not significantly different at other time-periods. (C) Runx2 mRNA expression in the hypoxic condition group was significantly higher than that 
in the normal condition group on day 1, but was not significantly different at other time-periods. (D) ALP mRNA expression in the hypoxic condition group 
was significantly higher than that in the normal condition group on days 1 and 2, but was not significantly different at other time-periods. (E) BSP mRNA 
expression in the hypoxic condition group was significantly higher than that in the normal condition group on days 2 and 3, but was not significantly different 
at other time-periods. (F) OCN mRNA expression in the hypoxic condition group was significantly higher than that in the normal condition group on day 4, but 
was not significantly different at other time-periods. (G) Periostin mRNA expression in the hypoxic condition group was significantly higher than that in the 
normal condition group on day 2, but was not significantly different at other time-periods. *P<0.05, **P<0.01. HIF1α, hypoxia-inducible factor; VEGF, vascular 
endothelial growth factor; ALP, alkaline phosphatase; BSP, bone sialoprotein; OCN, osteocalcin.
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hypoxic condition group than in the normal condition group on 
day 1 (P<0.05). ALP expression was significantly higher in the 
hypoxic condition group than in the normal condition group on 
days 1 and 2 (P<0.05). BSP expression was significantly higher 
in the hypoxic condition group than in the normal condition 
group on days 2 and 3 (P<0.05). OCN expression was signifi-
cantly higher in the hypoxic condition group than in the normal 
condition group on day 4 (P<0.05). In particular, a significantly 
high value was indicated on day 3 (P<0.01). Periostin expres-
sion was significantly higher in the hypoxic condition group 
than in the normal condition group on day 2 (P<0.05) (Fig. 2).
ALP activity. In comparison to the normal condition group, 
the hypoxic condition group demonstrated a higher (P<0.05) 
expression of ALP activity on day 4. However, there were no 
significant differences at the other time-periods (Fig. 3).
Protein expression. HIF1α, VEGF, BMP2, Runx2 and BSP 
were all expressed more strongly in the hypoxic condition cell 
group than in the normal condition group. Glut1, OCN and 
periostin were all expressed in both the normal and hypoxic 
condition groups (Fig. 4).
Discussion
It has been reported that osteogenic capability is just as 
remarkably high in periosteal cells as it is in bone marrow 
cells, which are the material typically used in bone regenera-
tion therapy (8). Pittenger et al reported that SH2 and SH3 are 
mesenchymal stem cell markers that differentiate into osteo-
blasts within bone marrow (17). Since then, the same markers 
have also been reported in the periosteum (18,19). Furthermore, 
Sakaguchi et al reported that there was no significant differ-
ence between periosteal and bone marrow cells in terms of 
the expression of CD44, CD90 and CD105, which are also 
mesenchymal stem cell markers (20). We observed that rat 
cultured bone marrow cells expressed the same markers as 
cultured periosteal cells using exactly the same antibodies as 
were used in this study (data not shown). Taken together, these 
results suggest that both periosteal and bone marrow cells have 
similar characteristics, in terms of their quality and quantity of 
stem cells and strong osteogenic capability.
In the maxillofacial area, the mandible has been cited as a 
collection site for actual periosteal transplants. The calvarial 
periosteum used in this study also originates from intramem-
branous ossification as in the mandibular bone. Jeroen et al (22) 
conducted comparisons of the periosteal osteogenic capability 
of rabbits and humans, and Krzysztof et al (21) conducted 
comparisons in chickens, dogs, mice and rats. Furthermore, 
Wei et al compared periosteum of the same size collected 
from the diaphyseal and epiphyseal region of the femurs 
of rats according to age (23,24). In these studies, there were 
differences in the speed of differentiation and the degree of 
osteogenic capability according to species, site and age, but they 
were mostly in agreement regarding cell kinetics. Therefore, 
this molecular biological study of cell kinetics using calvarial 
periosteal cells of rats may assist in the clinical application of 
human mandible periosteal cells.
Generally, it is known that the cell proliferation ratio 
changes according to the type of hypoxic condition that the 
cells are placed in (25-30). Also, the hypoxic condition affects 
the cell kinetics even when the same cells are used in the condi-
tion. Yoshida et al studied mouse embryonic fibroblasts in vitro 
with the oxygen condition set to 1, 5 and 20%, and found the 
number of colonies to be highest at the condition of 5% oxygen 
(31). Senzui et al reported that the cell count in rat pulp cells 
decreased at an oxygen condition of 5% (16). No significant 
difference was noted in the hypoxic condition at 5% oxygen 
in this study. These results shows that there is a marked differ-
ence in cell proliferation between rat periosteal cells and mouse 
embryonic fibroblasts under hypoxic conditions.
HIF1α is a hypoxia-inducible factor, and expressed in 
hypoxic conditions. Hanada et al reported that the expression 
of BMP2 raised the osteogenic capability of the periosteum 
(32). In this study, a stronger protein expression of BMP2 was 
noted in the hypoxic condition group than in the normal condi-
tion group. HIF1α induces hypoxia via integrin-linked kinase 
(ILK), Akt and the mammalian target of rapamycin (mTOR), 
causing BMP2 to be strongly expressed (33) and accelerating 
the cell differentiation.
In this study, the hypoxic condition group exhibited 
significantly and chronologically higher values than the normal 
Figure 3. Alkaline phosphatase (ALP) activity. Compared to the normal con-
dition group, the hypoxic condition group demonstrated a higher expression 
of ALP activity on day 4. *P<0.05, **P<0.01
Figure 4. Protein expression. We carried out an evaluation of the normal and 
the hypoxic condition group on day 4 after the incubation. HIF1α, VEGF, 
BMP2, Runx2 and BSP were all expressed more strongly in the hypoxic 
condition cell group than in the normal condition group. Glut1, OCN and 
periostin were all expressed in both the normal and hypoxic condition groups. 
HIF1α, hypoxia-inducible factor; VEGF, vascular endothelial growth factor; 
BMP2, bone morphogenetic protein 2; ALP, alkaline phosphatase; BSP, bone 
sialoprotein; OCN, osteocalcin.
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condition group which may suggest that periosteal cells are 
resistant to hypoxia. In this study, Glut1 and VEGF have been 
cited as being strongly expressed at either the protein or mRNA 
level in hypoxic conditions. Glut1, which comprises 5% of red 
blood cell membrane protein, activates the glycolytic pathways, 
and VEGF activates angiogenesis and HIF1α is closely related to 
osteogenic capability (34-38). HIF1α binds to hypoxia response 
elements located in the gene promoters to regulate the transcrip-
tion of VEGF and Glut1 (39). Runx2 is an initial transcription 
factor for the differentiation process of osteoblasts. Komori et al 
(40) and Otto et al (41) proved that Runx2 gene is vital to the 
differentiation and osteogenesis of osteoblasts since in Runx2 
knockout mice, osteoblast differentiation is clearly suppressed 
and osteoblast formation does not take place. Kobayashi et al 
proved that although neither endochondral ossification nor 
intramembranous ossification occur in Runx2 knockout mice, 
since the differentiation of damaged mesenchymal cells into 
adipocytes and chondrocytes is possible, it is an essential factor 
in the initial stage of osteoblast differentiation (42). Liu et al 
reported that although Runx2 functions as an accelerator in 
the initial stage of osteoblast differentiation, it inhibits mature 
osteoblasts and osteocytes (43). In this study, both mRNA and 
protein levels of Runx2 were strongly expressed in the hypoxic 
incubation group. This suggests that periosteal cells, which 
might include pre-osteoblast stage cells, react to the hypoxic 
condition. ALP is known to be a marker for early osteogenesis, 
BSP is known to be a marker for pre-calcification, and OCN is 
known to be a marker for post-calcification (44). In this study, 
both these markers showed higher expression at both the protein 
and mRNA level in the hypoxic condition group. In particular, 
BSP was more strongly expressed on days 2 and 3 and OCN 
was more strongly expressed on day 4 in the hypoxic condition 
group. It would appear that a hypoxic condition is also effective 
for osteoblasts to mature to osteocytes. 
Periostin, which is known to be a specifically expressed 
protein of the osteoblastic cells of the periodontal ligament 
and periosteum, was strongly expressed at the mRNA level 
in the hypoxic condition group in this study. Hiouchi et al 
reported that periostin existed only in the periosteum, and was 
expressed in the periodontal ligament induced by some kind of 
mechanical stress (45). Kudo et al (47) as well as others (46,48) 
reported that periostin affects the ligands α-V/β3 and α-V/ β5, 
and is involved in the angiogenesis of malignant tumors. 
Another report suggests that periostin is involved in the phos-
phorylation of FAK and Akt in αv-integrin pathways during 
the recovery process following a myocardial infarction (49). 
The fact that Akt is a factor in the upregulation of HIF1α (50) 
suggests that there must be a significant correlation between 
periostin and hypoxic conditions.
In conclusion, hypoxic conditions activate the osteogenic 
capability of periosteal cells in rats.
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